Parkinson disease incidence lower in hep C patients who receive antivirals

Parkinson disease incidence lower in hep C patients who receive antivirals

(HealthDay)—The incidence of Parkinson disease (PD) is lower for patients with chronic hepatitis C virus (HCV) infection who receive interferon-based antiviral therapy, according to a study published online June 5 in JAMA Neurology.

Wey-Yil Lin, M.D., from Landseed International Hospital in Taoyuan, Taiwan, and colleagues examined the risk for PD development in patients with HCV infection receiving and those not receiving treatment using claims data obtained from the Taiwan National Health Insurance Research Database. A total of 188,152 patients were categorized into treated and untreated groups. For comparison of main outcomes, propensity score matching was performed to balance the covariates across groups; 39,936 patients were retained in the treated and untreated groups.

The researchers found that the incidence density of PD was 1.00 and 1.39 per 1,000 person-years in the treated and untreated groups, respectively. At five-year follow-up, the advantage of reached (hazard ratio, 0.75); this advantage continued to increase until the end of follow-up (hazard ratio, 0.71).

"The results seem to support the theory that HCV infection is a risk factor for developing PD. Antiviral therapy has shown potential in lowering this risk," the authors write.


Explore further

Incidence of Parkinson disease increased in bipolar disorder

More information: Abstract/Full Text
Editorial (subscription or payment may be required)
Journal information: Archives of Neurology

Copyright © 2019 HealthDay. All rights reserved.

Citation: Parkinson disease incidence lower in hep C patients who receive antivirals (2019, June 6) retrieved 13 October 2019 from https://medicalxpress.com/news/2019-06-parkinson-disease-incidence-hep-patients.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more